Metastatic Castration-resistant Prostate Cancer Clinical Trials in Chicago, Illinois

5 studies are recruiting for metastatic castration-resistant prostate cancer in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

    The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Illinois Chicago, Chicago, Illinois
    Locations
    155 in total
    Run by
    Amgen

    See if you can join NCT07213674 on ClinicalTrials.gov

  2. A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

    The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid t…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Chicago Medical Center, Chicago, Illinois
    Locations
    80 in total
    Run by
    Novartis Pharmaceuticals

    See if you can join NCT04104776 on ClinicalTrials.gov

  3. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

    Stage
    Phase 1
    Ages
    18 to 100
    Site
    University of Chicago Medical Center, Chicago, Illinois
    Locations
    36 in total
    Run by
    Janux Therapeutics

    See if you can join NCT05519449 on ClinicalTrials.gov

  4. A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

    The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Chicago, Chicago, Illinois
    Locations
    23 in total
    Run by
    Syncromune, Inc.

    See if you can join NCT06533644 on ClinicalTrials.gov

  5. A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

    The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Site, Chicago, Illinois
    Locations
    16 in total
    Run by
    AstraZeneca

    See if you can join NCT06879041 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.